Filed: 2026-04-16 AccNo: 0001493152-26-016979 Size: 299 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
NS
Article DetailSEC EDGAR Filings
SEC EDGAR Filings
8-K - Aspire Biopharma Holdings, Inc. - 7.01 / 9.01
Filed:
2026-04-20
AccNo:
0001493152-26-018018
Size:
295 KB
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits
发布时间04/20 13:00 UTC
首次发现04/20 13:00 UTC
热度105.4
重要度64
情绪0.00
站内整理正文
优先显示结构化正文；如果正文还未抽出，则回退到摘要。
sec_edgar_index_v1 · 701 字符
Form 8-K - Current report: SEC Accession No. 0001493152-26-018018
Filing Date: 2026-04-20
Accepted: 2026-04-20 09:00:14
Documents: 14
Period of Report: 2026-04-20
Items: Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Aspire Biopharma Holdings, Inc. (Filer) CIK : 0001847345 (see all company filings) EIN. : 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-41293 | Film No.: 26873491 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)
1 | 8-K | form8-k.htm iXBRL | 8-K
2 | EX-99.1 | ex99-1.htm | EX-99.1
3 | GRAPHIC | ex99-1_001.jpg | GRAPHIC
4 | XBRL SCHEMA FILE | asbp-20260420.xsd | EX-101.SCH
同簇相关文章
从当前文章回到同一事件簇里的其他来源或补充材料。
1 篇